3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
317
Rectal Neoplasms
235
Stomach Neoplasms
209
Pancreatic Neoplasms
137
Colonic Neoplasms
94
Neoplasm Metastasis
60
Esophageal Neoplasms
57
Neoplasms
40
Biliary Tract Neoplasms
39
Cholangiocarcinoma
31
Carcinoma, Hepatocellular
30
Gallbladder Neoplasms
29
Breast Neoplasms
28
Adenocarcinoma
22
Bile Duct Neoplasms
21
Locally Advanced Rectal Cancer
20
Adenocarcinoma Of Esophagus
20
Gastrointestinal Neoplasms
18
Liver Neoplasms
17
Esophageal Squamous Cell Carcinoma
17
Colorectal Cancer Metastatic
15
Carcinoma, Non-Small-Cell Lung
12
Anus Neoplasms
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Digestive System Neoplasms
7
Carcinoma
7
Advanced Gastric Cancer
7
Squamous Cell Carcinoma of Head and Neck
6
Ovarian Neoplasms
6
Klatskin Tumor
6
Interventions
Specimen Handling
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
pembrolizumab
1
Ipilimumab
1
Interleukin-2
1
IFL protocol
1
HhAntag691
1
Folfox protocol
1
Capecitabine
1
CTLA-4 Antigen
1
Bevacizumab
1
Antineoplastic Protocols
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
Capecitabine
×
Gastrointestinal
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled